Income statement
CAD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 95K | 49K | 68K | 0 | 36K |
| Gross Profit | 95K | 42K | 58K | -49K | 26K |
| Operating Income | -5M | -5M | -5M | -4M | -2M |
| EBITDA | -5M | -5M | -5M | -4M | -2M |
| Net Income | -5M | -5M | -5M | -4M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.085
+0.58% today
1Y Change
-22.44%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VentriPoint Diagnostics Ltd. (VPTDF) is a Healthcare stock with a market cap of $30.00M and listed on OTC. The stock last traded around $0.08 and down 22.4% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +93.5%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue +93.5%, EPS 0.0%, free cash flow +11.0% with operating margin -2113.8% and ROIC 157.5%. Valuation already assumes a fairly strong business story at price/sales 160.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VPTDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VPTDF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VPTDF Max Drawdown
-52.42%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VPTDF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$36.0K
FY Net Income
-$1.9M
+52.3% YoY
Free Cash Flow
-$1.1M
+65.0% YoY
Revenue Growth
+93.5%
EPS Growth
+0.0%
Gross Margin
82.5%
Net Margin
-2311.8%
Income statement
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 95K | 49K | 68K | 0 | 36K |
| Gross Profit | 95K | 42K | 58K | -49K | 26K |
| Operating Income | -5M | -5M | -5M | -4M | -2M |
| EBITDA | -5M | -5M | -5M | -4M | -2M |
| Net Income | -5M | -5M | -5M | -4M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 61K | 1M | 5M | 9M | 526K |
| Total Assets | 658K | 2M | 6M | 10M | 802K |
| Total Liabilities | 4M | 2M | 1M | 1M | 3M |
| Shareholder Equity | -3M | 190K | 5M | 8M | -2M |
| Total Debt | 2M | 412K | 459K | 160K | 1M |
| Net Debt | 2M | -882K | -5M | -9M | 844K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+65.0% YoY
Capital Expenditures
4K
+11.6% YoY
Free Cash Flow
1M
+65.0% YoY
Key ratios
Gross Margin
82.5%
Operating Margin
-2113.8%
Net Margin
-2311.8%
ROE
106.7%
Debt / Equity
-0.50x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.